Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2014

Open Access 01-01-2014 | Clinical trial

Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer?

Authors: Andrew Evans, Petra Rauchhaus, Patsy Whelehan, Kim Thomson, Colin A. Purdie, Lee B. Jordan, Caroline O. Michie, Alastair Thompson, Sarah Vinnicombe

Published in: Breast Cancer Research and Treatment | Issue 1/2014

Login to get access

Abstract

Shear wave elastography (SWE) shows promise as an adjunct to greyscale ultrasound examination in assessing breast masses. In breast cancer, higher lesion stiffness on SWE has been shown to be associated with features of poor prognosis. The purpose of this study was to assess whether lesion stiffness at SWE is an independent predictor of lymph node involvement. Patients with invasive breast cancer treated by primary surgery, who had undergone SWE examination were eligible. Data were retrospectively analysed from 396 consecutive patients. The mean stiffness values were obtained using the Aixplorer® ultrasound machine from SuperSonic Imagine Ltd. Measurements were taken from a region of interest positioned over the stiffest part of the abnormality. The average of the mean stiffness value obtained from each of two orthogonal image planes was used for analysis. Associations between lymph node involvement and mean lesion stiffness, invasive cancer size, histologic grade, tumour type, ER expression, HER-2 status and vascular invasion were assessed using univariate and multivariate logistic regression. At univariate analysis, invasive size, histologic grade, HER-2 status, vascular invasion, tumour type and mean stiffness were significantly associated with nodal involvement. Nodal involvement rates ranged from 7 % for tumours with mean stiffness <50 kPa to 41 % for tumours with a mean stiffness of >150 kPa. At multivariate analysis, invasive size, tumour type, vascular invasion, and mean stiffness maintained independent significance. Mean stiffness at SWE is an independent predictor of lymph node metastasis and thus can confer prognostic information additional to that provided by conventional preoperative tumour assessment and staging.
Literature
1.
go back to reference Berg WA, Cosgrove DO, Dore CJ, Schaefer FKW, Svensson WE, Hooley RJ, Ohlinger R, Mendelson EB, Balu-Maestro C, Locatelli M, Tourasse C, Cavanaugh BC, Juhan V, Stavros AT, Tardivon A, Gay J, Henry JP, Cohen-Bacrie C (2012) Shear-wave elastography improves the specificity of breast US: the BE1 multinational study of 939 masses. Radiology 262(2):435–449PubMedCrossRef Berg WA, Cosgrove DO, Dore CJ, Schaefer FKW, Svensson WE, Hooley RJ, Ohlinger R, Mendelson EB, Balu-Maestro C, Locatelli M, Tourasse C, Cavanaugh BC, Juhan V, Stavros AT, Tardivon A, Gay J, Henry JP, Cohen-Bacrie C (2012) Shear-wave elastography improves the specificity of breast US: the BE1 multinational study of 939 masses. Radiology 262(2):435–449PubMedCrossRef
2.
go back to reference Chang JM, Moon WK, Cho N, Yi A, Koo HR, Han W, Noh DY, Moon HG, Kim SJ (2011) Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases. Breast Cancer Res Treat 129(1):89–97PubMedCrossRef Chang JM, Moon WK, Cho N, Yi A, Koo HR, Han W, Noh DY, Moon HG, Kim SJ (2011) Clinical application of shear wave elastography (SWE) in the diagnosis of benign and malignant breast diseases. Breast Cancer Res Treat 129(1):89–97PubMedCrossRef
3.
go back to reference Evans A, Whelehan P, Thomson K, Brauer K, Jordan L, Purdie C, McLean D, Baker L, Vinnicombe S, Thompson A (2012) Differentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification. Br J Cancer 107(2):224–229PubMedCentralPubMedCrossRef Evans A, Whelehan P, Thomson K, Brauer K, Jordan L, Purdie C, McLean D, Baker L, Vinnicombe S, Thompson A (2012) Differentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification. Br J Cancer 107(2):224–229PubMedCentralPubMedCrossRef
4.
go back to reference Regner D, Hesley G, Hangiandreou N, Morton M, Nordland M, Meixner D, Hall T, Farrell M, Mandrekar J, Harmsen W, Charboneau J (2006) Breast lesions: evaluation with US strain imaging—clinical experience of multiple observers. Radiology 238:425–437PubMedCentralPubMedCrossRef Regner D, Hesley G, Hangiandreou N, Morton M, Nordland M, Meixner D, Hall T, Farrell M, Mandrekar J, Harmsen W, Charboneau J (2006) Breast lesions: evaluation with US strain imaging—clinical experience of multiple observers. Radiology 238:425–437PubMedCentralPubMedCrossRef
5.
go back to reference Burnside ES, Hall TJ, Sommer AM, Hesley GK, Sisney GA, Svensson WE, Fine JP, Jiang J, Hangiandreou NJ (2007) Differentiating benign from malignant solid breast masses with US strain imaging. Radiology 245(2):401–410PubMedCrossRef Burnside ES, Hall TJ, Sommer AM, Hesley GK, Sisney GA, Svensson WE, Fine JP, Jiang J, Hangiandreou NJ (2007) Differentiating benign from malignant solid breast masses with US strain imaging. Radiology 245(2):401–410PubMedCrossRef
6.
go back to reference Cosgrove DO, Berg WA, Dore CJ, Skyba DM, Henry JP, Gay J, Cohen-Bacrie C (2012) Shear wave elastography for breast masses is highly reproducible. Eur Radiol 22(5):1023–1032PubMedCentralPubMedCrossRef Cosgrove DO, Berg WA, Dore CJ, Skyba DM, Henry JP, Gay J, Cohen-Bacrie C (2012) Shear wave elastography for breast masses is highly reproducible. Eur Radiol 22(5):1023–1032PubMedCentralPubMedCrossRef
7.
go back to reference Youk JH, Gweon HM, Son EJ, Kim JA, Jeong J (2013) Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemical profile. Breast Cancer Res Treat 138(1):119–126PubMedCrossRef Youk JH, Gweon HM, Son EJ, Kim JA, Jeong J (2013) Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemical profile. Breast Cancer Res Treat 138(1):119–126PubMedCrossRef
8.
go back to reference Evans A, Whelehan P, Thomson K, McLean D, Brauer K, Purdie C, Baker L, Jordan L, Rauchhaus P, Thompson A (2012) Invasive breast cancer: relationship between shear-wave elastographic findings and histologic prognostic factors. Radiology 263(3):673–677PubMedCrossRef Evans A, Whelehan P, Thomson K, McLean D, Brauer K, Purdie C, Baker L, Jordan L, Rauchhaus P, Thompson A (2012) Invasive breast cancer: relationship between shear-wave elastographic findings and histologic prognostic factors. Radiology 263(3):673–677PubMedCrossRef
9.
go back to reference Fitzgibbons PL, Page DL, Weaver D, Thor AD, Craig Allred D, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. Arch Pathol Lab Med 124(7):966–978PubMed Fitzgibbons PL, Page DL, Weaver D, Thor AD, Craig Allred D, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. Arch Pathol Lab Med 124(7):966–978PubMed
10.
go back to reference Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC (2013) Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions. J Natl Cancer Inst 105(2):104–112PubMedCrossRef Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC (2013) Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions. J Natl Cancer Inst 105(2):104–112PubMedCrossRef
11.
go back to reference Bevilacqua JLB, Kattan MW, Fey JV, Cody Iii HS, Borgen PI, Van Zee KJ (2007) Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol 25(24):3670–3679PubMedCrossRef Bevilacqua JLB, Kattan MW, Fey JV, Cody Iii HS, Borgen PI, Van Zee KJ (2007) Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol 25(24):3670–3679PubMedCrossRef
12.
go back to reference Qiu PF, Liu JJ, Wang YS, Yang GR, Liu YB, Sun X, Wang CJ, Zhang ZP (2012) Risk factors for sentinel lymph node metastasis and validation study of the MSKCC nomogram in breast cancer patients. Jpn J Clin Oncol 42(11):1002–1007PubMedCrossRef Qiu PF, Liu JJ, Wang YS, Yang GR, Liu YB, Sun X, Wang CJ, Zhang ZP (2012) Risk factors for sentinel lymph node metastasis and validation study of the MSKCC nomogram in breast cancer patients. Jpn J Clin Oncol 42(11):1002–1007PubMedCrossRef
13.
go back to reference Houssami N, Ciatto S, Turner RM, Cody HS, MacAskill P (2011) Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 254(2):243–251PubMedCrossRef Houssami N, Ciatto S, Turner RM, Cody HS, MacAskill P (2011) Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 254(2):243–251PubMedCrossRef
14.
go back to reference National Research Ethics Service (2008) Approval for medical devices research: guidance for researchers, manufacturers, research ethics committees and NHS R&D offices (Version 2). National Patient Safety Agency, London National Research Ethics Service (2008) Approval for medical devices research: guidance for researchers, manufacturers, research ethics committees and NHS R&D offices (Version 2). National Patient Safety Agency, London
15.
go back to reference Guidelines working group of the national coordinating committee for breast pathology (2005) Pathology reporting of breast disease (NHSBSP publication 58). NHS Cancer Screening Programmes & The Royal College of Pathologists, London Guidelines working group of the national coordinating committee for breast pathology (2005) Pathology reporting of breast disease (NHSBSP publication 58). NHS Cancer Screening Programmes & The Royal College of Pathologists, London
16.
go back to reference Purdie CA, Jordan LB, McCullough JB, Edwards SL, Cunningham J, Walsh M, Grant A, Pratt N, Thompson AM (2010) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56(6):702–707PubMedCrossRef Purdie CA, Jordan LB, McCullough JB, Edwards SL, Cunningham J, Walsh M, Grant A, Pratt N, Thompson AM (2010) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56(6):702–707PubMedCrossRef
17.
go back to reference Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ (2011) Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 178(3):1221–1232PubMedCrossRef Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ (2011) Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 178(3):1221–1232PubMedCrossRef
18.
go back to reference Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SFT, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906PubMedCentralPubMedCrossRef Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SFT, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906PubMedCentralPubMedCrossRef
19.
go back to reference Chen LC, Tu SH, Huang CS, Chen CS, Ho CT, Lin HW, Lee CH, Chang HW, Chang CH, Wu CH, Lee WS, Ho YS (2012) Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway. Breast Cancer Research Treat. doi:10.1007/s10549-012-1986-8 Chen LC, Tu SH, Huang CS, Chen CS, Ho CT, Lin HW, Lee CH, Chang HW, Chang CH, Wu CH, Lee WS, Ho YS (2012) Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway. Breast Cancer Research Treat. doi:10.​1007/​s10549-012-1986-8
20.
go back to reference Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, MacGrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15(1):68–74PubMedCrossRef Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, MacGrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15(1):68–74PubMedCrossRef
21.
go back to reference Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174(6):2023–2034PubMedCrossRef Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP (2009) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174(6):2023–2034PubMedCrossRef
22.
go back to reference Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, ChacÃn JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873–1881PubMedCrossRef Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, ChacÃn JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873–1881PubMedCrossRef
23.
go back to reference Kandemir NO, Barut F, Bektas S, Ozdamar SO (2012) Can lymphatic vascular density be used in determining metastatic spreading potential of tumor in invasive ductal carcinomas? Pathol Oncol Res 18(2):253–262PubMedCrossRef Kandemir NO, Barut F, Bektas S, Ozdamar SO (2012) Can lymphatic vascular density be used in determining metastatic spreading potential of tumor in invasive ductal carcinomas? Pathol Oncol Res 18(2):253–262PubMedCrossRef
24.
go back to reference Kwok TC, Rakha EA, Lee AHS, Grainge M, Green AR, Ellis IO, Powe DG (2010) Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology 57(2):212–219PubMedCentralPubMedCrossRef Kwok TC, Rakha EA, Lee AHS, Grainge M, Green AR, Ellis IO, Powe DG (2010) Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology 57(2):212–219PubMedCentralPubMedCrossRef
25.
go back to reference O’Shea AM, Rakha EA, Hodi Z, Ellis IO, Lee AHS (2011) Histological grade of invasive carcinoma of the breast assessed on needle core biopsy—modifications to mitotic count assessment to improve agreement with surgical specimens. Histopathology 59(3):543–548PubMedCrossRef O’Shea AM, Rakha EA, Hodi Z, Ellis IO, Lee AHS (2011) Histological grade of invasive carcinoma of the breast assessed on needle core biopsy—modifications to mitotic count assessment to improve agreement with surgical specimens. Histopathology 59(3):543–548PubMedCrossRef
26.
go back to reference Boughey J, Suman V, Mittendorf E, Ahrendt G, Wilke L, Taback B, Leitch A, Flippo-Morton T, Byrd D, Ollila D, Julian T, McLaughlin S, McCall L, Symmans W, Le-Petross H, Haffty B, Buchholz T (2012) The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy—results from the ACOSOG Z1071 trial. Cancer Res 72((24 Suppl.)):Abstract nr S2-1 Boughey J, Suman V, Mittendorf E, Ahrendt G, Wilke L, Taback B, Leitch A, Flippo-Morton T, Byrd D, Ollila D, Julian T, McLaughlin S, McCall L, Symmans W, Le-Petross H, Haffty B, Buchholz T (2012) The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy—results from the ACOSOG Z1071 trial. Cancer Res 72((24 Suppl.)):Abstract nr S2-1
27.
go back to reference Kuehn T, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M (2012) Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial. Cancer Res 72((24 Suppl.)):Abstract nr S2-2 Kuehn T, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M (2012) Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial. Cancer Res 72((24 Suppl.)):Abstract nr S2-2
Metadata
Title
Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer?
Authors
Andrew Evans
Petra Rauchhaus
Patsy Whelehan
Kim Thomson
Colin A. Purdie
Lee B. Jordan
Caroline O. Michie
Alastair Thompson
Sarah Vinnicombe
Publication date
01-01-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2747-z

Other articles of this Issue 1/2014

Breast Cancer Research and Treatment 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine